Embecta Corp
$ 10.28
-2.74%
24 Feb - close price
- Market Cap 625,954,000 USD
- Current Price $ 10.28
- High / Low $ 10.77 / 10.22
- Stock P/E 4.48
- Book Value -10.35
- EPS 2.36
- Next Earning Report 2026-05-08
- Dividend Per Share $0.60
- Dividend Yield 5.59 %
- Next Dividend Date 2026-03-17
- ROA 0.18 %
- ROE N/A %
- 52 Week High 15.35
- 52 Week Low 8.99
About
Embecta Corp (EMBC) is a premier global medical technology company focused on diabetes management solutions, particularly through its advanced insulin delivery devices. Originating as a spin-off from Becton, Dickinson and Company, Embecta harnesses innovative technology to improve patient experience and health outcomes. The company offers a robust portfolio, including insulin pens and syringes, underscoring its commitment to enhancing diabetes care. With a strategic focus on operational excellence and customer-centric initiatives, Embecta is well-positioned for sustainable growth in the dynamic diabetes care market.
Analyst Target Price
$16.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-11-25 | 2025-08-08 | 2025-05-07 | 2025-02-07 | 2024-11-19 | 2024-08-09 | 2024-05-09 | 2024-02-09 | 2023-11-21 | 2023-08-08 | 2023-05-12 |
| Reported EPS | 0.71 | 0.5 | 0.78 | 0.7 | 0.65 | 0.45 | 0.74 | 0.67 | 0.61 | 0.59 | 0.26 | 0.24 |
| Estimated EPS | 0.67 | 0.46 | 0.77 | 0.5875 | 0.4425 | 0.36 | 0.46 | 0.4 | 0.46 | 0.4 | 0.46 | 0.49 |
| Surprise | 0.04 | 0.04 | 0.01 | 0.1125 | 0.2075 | 0.09 | 0.28 | 0.27 | 0.15 | 0.19 | -0.2 | -0.25 |
| Surprise Percentage | 5.9701% | 8.6957% | 1.2987% | 19.1489% | 46.8927% | 25% | 60.8696% | 67.5% | 32.6087% | 47.5% | -43.4783% | -51.0204% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.6678 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-17 | 2025-12-18 | 2025-09-15 | 2025-06-13 | 2025-03-14 | 2024-12-18 | 2024-09-13 | 2024-06-14 | 2024-03-15 | 2023-12-15 |
| Amount | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 |
Next Dividend Records
| Dividend per share (year): | $0.60 |
| Dividend Yield | 5.59% |
| Next Dividend Date | 2026-03-17 |
| Ex-Dividend Date | 2026-02-27 |
Recent News: EMBC
2026-02-20 12:19:27
The Public Sector Pension Investment Board significantly increased its stake in Embecta Corp. by 57.7% in Q3, owning 314,129 shares valued at approximately $4.43 million. This comes amid heavy institutional accumulation, with 93.83% of Embecta stock held by institutions. Embecta recently surpassed Q3 earnings and revenue expectations, provided positive FY2026 guidance, and declared a quarterly dividend of $0.15 for a 5.7% yield, while analysts maintain a consensus "Hold" rating.
2026-02-19 16:27:21
The article provides a technical analysis of Embecta Corp. (NASDAQ: EMBC), highlighting divergent sentiment across different time horizons, which suggests choppy conditions. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also details AI-generated signals and support/resistance levels across near-term, mid-term, and long-term timeframes.
2026-02-15 11:57:35
At its Annual Meeting on February 11, 2026, Embecta Corporation shareholders re-elected all seven board nominees, including CEO Devdatt Kurdikar and chair Carrie L. Anderson. They also ratified Ernst & Young LLP as the independent auditor for fiscal 2026 and approved the compensation of named executive officers. Additionally, an amendment to the 2022 Employee and Director Equity-Based Compensation Plan was endorsed to strengthen the company's ability to use equity incentives.
2026-02-15 11:05:15
Embecta Corp. director Karen Prange reported the acquisition of 22,841 shares of common stock on February 11, 2026, as a grant or other award at a price of $0.00 per share. Following this transaction, Prange directly beneficially owned 64,581.208 shares, which includes stock dividends. This Form 4 filing indicates a neutral impact and sentiment regarding the insider trading activity.
2026-02-13 22:27:54
Embecta shareholders re-elected all directors, including CEO Devdatt Kurdikar and chair Carrie L. Anderson, and ratified Ernst & Young as the independent auditor for fiscal 2026. They also approved executive compensation and an amendment to the 2022 equity plan to better align management and director interests with shareholder value. Despite balance-sheet risks and weak technical momentum, Embecta shows strong cash generation and an attractive valuation.
2026-02-13 01:27:55
Embecta Corp. (Nasdaq: EMBC) has announced new leadership appointments to its Board of Directors. Devdatt "Dev" Kurdikar has been elected as Chairman of the Board, and Dr. Claire Pomeroy has been appointed as Lead Independent Director, effective immediately. These changes follow the retirement of LTG (Ret.) David F. Melcher, the previous Non-Executive Chairman.
